Calgary, Alberta — February 19, 2026 — Leads & Copy — Resverlogix Corp. (TSX: RVX) has announced the closing of a $2.8 million shares-for-interest private placement with an immediate family member of the company’s Chairman and CEO.
Under the terms of the transaction, the Subscriber purchased 28,000,000 common shares at CAD$0.10 per share, totaling CAD$2.8 million. Following the transaction, the Subscriber now holds approximately 9.7% of Resverlogix’s common shares. These shares are subject to a four-month hold period.
The shares-for-interest transaction was preceded by the settlement of CAD$2.8 million of accrued interest on indebtedness owed to the Subscriber by Zenith Capital Corp. This settlement was facilitated by the assignment to the Subscriber of an equal amount of accrued interest on indebtedness owed by Resverlogix to Zenith Capital Corp.
The securities mentioned have not been registered under the United States Securities Act of 1933, nor any state securities laws. Consequently, they may not be offered or sold to persons in the United States or to U.S. Persons, except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of Resverlogix’s securities to persons in the United States or U.S. Persons.
Resverlogix, founded in 2001 and based in Calgary, is a late-stage biotechnology company focused on epigenetics, aiming to develop therapies for patients with chronic diseases.
The company is developing epigenetic therapies designed to regulate the expression of disease-causing genes, with the goal of improving patients’ lives by restoring biological functions altered by illnesses such as cardiovascular disease.
Resverlogix’s clinical program is focused on evaluating apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.
Resverlogix common shares are traded on the Toronto Stock Exchange (TSX: RVX).
Source: Resverlogix
